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A 76-year-old woman with type II diabetes and hypertension
was diagnosed with gastrointestinal stromal tumor. At the
time of diagnosis, she was on insulin glargine 10 U daily
and atenolol 50 mg daily. She had a blood pressure (BP) of
104/58 mm Hg, serum creatinine (SCr) of 1.2 mg per 100 ml,
and no proteinuria. For treatment of the gastrointestinal
stromal tumor, she was started on imatinib mesylate. Sixteen
months into this therapy, the tumor progressed. At that
point, she had a BP of 130/78 mm Hg, weight of 53.4 kg,
SCr of 1.2 mg per 100 ml, and still no proteinuria. Imatinib
was replaced with sunitinib 37.5 mg daily (Sutent).
Over the next 20 weeks, her BP gradually rose to 166/
76 mm Hg. A total of 30 weeks after initiation of sunitinib,
her BP was 142/49 mm Hg, weight was 59.2 kg, SCr was
2.4 mg per 100 ml, and protein/creatinine ratio was 7.2 (g/g).
When she was first seen in the renal clinic 3 months later,
her BP was 156/69 mm Hg, weight was 59.4 kg, jugular
venous pressure was 6 cm, cardiopulmonary examination
was unremarkable, renal artery bruits were not appreciated,
but 1þ pitting pedal edema was present. Urinalysis showed
3þ protein with a bland sediment. SCr was 1.8 mg per
100 ml and urine protein/creatinine was 10.4 (g/g) (Figure 1).
Serum complement and protein electrophoreses were
normal; ANA, cryoglobulin, and rheumatoid factor were
negative; and there was no evidence of microangiopathic
hemolysis.
What is the diagnosis?
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Figure 1 | Development and resolution of
proteinuria during sunitinib treatment. Patient
2 from a published case series (1) had no
proteinuria after 1 month of therapy but
developed a protein/creatinine ratio of 7.2 (g/g)
after 30 weeks of therapy and 10.4 (g/g) after
44 weeks. Proteinuria, hypertension and
acute kidney injury completely resolved within
24 weeks of stopping sunitinib.
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The Diagnosis | Sunitinib-induced preeclampsia-like
syndrome
The clinical diagnosis was a preeclampsia-like syndrome
associated with the anti-angiogenic agent sunitinib. Thrombo-
cytopenia prohibited renal biopsy. Sunitinib was discontinued,
and within 24 weeks, proteinuria had resolved completely and
SCr had returned to 1.2 mg per 100 ml (Figure 1).
Sunitinib is a member of a novel class of multitargeted,
small molecule tyrosine kinase inhibitors that block the activity
of multiple enzymes, including the vascular endothelial growth
factor receptor (VEGF-R; Table 1). These chemotherapies are
also associated with development of hypertension, proteinuria,
and azotemia in at least 2.3% of patients receiving them.1 This
clinical syndrome is similar to preeclampsia, in which
disordered VEGF signaling plays a crucial role.2 The renal
pathology in most patients reported to date is that of
thrombotic microangiopathy, and genetic evidence in a mouse
model implicates glomerular VEGF inhibition in the patho-
genesis of this condition (Figure 2).3 The renal toxicities of
molecule tyrosine kinase inhibitors add to growing evidence
that VEGF is required for endothelial cell homeostasis,
especially in the glomerular endothelial cell bed.4
Our experience suggests that some patients can be main-
tained on anti-angiogenic therapies despite development
of hypertension and proteinuria. Tight control of BP
with inhibitors of angiotensin signaling, diuretics, and, if
necessary, calcium channel blockers may allow patients to
continue anti-angiogenic therapy. However, the long-term
renal consequences of anti-angiogenic therapy in patients
who do develop hypertension and/or proteinuria, remain
unknown. If, as in this case, nephrotic-range proteinuria,
hypertension with end-organ consequences, or renal failure
develops, dose reduction, extended washout, or discontinua-
tion of therapy should be considered. Before prescribing
immunosuppressive medications or in cases with atypical
clinical features, an active urinary sediment or positive
laboratory findings, renal biopsy should be performed to
exclude other renal diseases.
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Figure 2 | Mechanisms of vascular endothelial growth factor (VEGF) inhibition by anti-angiogenic therapies in the glomerulus. VEGF
is produced by podocytes, where it may act in a paracrine fashion on glomerular capillary endothelial cells. VEGF is also produced by
endothelial cells, where it signals in an autocrine manner to maintain endothelial cell differentiation. Bevacizumab binds and depletes free,
circulating VEGF but does not inhibit autocrine VEGF signaling pathways that do not involve extracellular VEGF secretion. Sorafenib and
sunitinib inhibit the intracellular tyrosine kinase activity of the VEGF receptor, among other tyrosine kinases, and therefore disrupt both
paracrine and autocrine VEGF signaling.
Table 1 | FDA-approved anti-angiogenic therapies
Agent Class Mechanism of action FDA approval
Sunitinib Small molecule Tyrosine kinase inhibitor of VEGFR, PDGFR RCC, GIST
Sorafenib Small molecule Tyrosine kinase inhibitor of VEGFR, PDGFR, and Ras RCC, HCC
Bevacizumab Monoclonal antibody VEGF-depleting antibody Colon cancer, NSCLC, breast cancer
GIST, gastrointestinal stromal tumor; HCC, hepatocellular carcinoma; NSCLC, non-small-cell lung cancer; PDGFR, platelet-derived growth factor receptor; RCC, renal cell
carcinoma; VEGFR, vascular endothelial growth factor receptor.
686 Kidney International (2008) 74, 685–686
M a k e y o u r d i a g n o s i s JS Obhrai et al.: Toxicities of anti-angiogenic therapy
